Press releaseGlobe Newswire
Evofem Biosciences
EVFM · OTC
$0.0063+$0.00 (+0.00%)TodayMarket closed ·
Prev close $0.0063
Latest news
- Press releasePRNewswire
Favorable Pricing Certificates Issued for Evofem's PHEXX by Emirates Drug Establishment are Launching Step for Commercialization in UAE
- Press releasePRNewswire
Evofem Reports Financial Results for Third Quarter of 2025, Provides Business Update
- Press releasePRNewswire
Evofem Announces Voting Results from Special Meeting of Stockholders
- Press releasePRNewswire
Evofem's SOLOSEC Submitted for Marketing Approval in United Arab Emirates
- Press releasePRNewswire
Evofem Biosciences Honors World Contraception Day
- Press releasePRNewswire
Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms
- Press releasePRNewswire
Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting
- Press releasePRNewswire
Illinois Pharmacists Can Prescribe PHEXXI Starting January 2026 Under Newly-passed Law
- Press releasePRNewswire
FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences' "One and Done" Oral Treatment for Bacterial Vaginosis and Trichomoniasis
- Press releasePRNewswire
Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update
- Press releasePRNewswire
Evofem CEO Saundra Pelletier Honored with Trailblazing Female Founders Award at STIMULATE Conference
- Press releasePRNewswire
Phexxi -- A Non‑Hormonal Birth Control Brand -- Goes Viral with Microfeminism on TikTok, Featured by BuzzFeed and Scary Mommy
- Press releasePRNewswire
Evofem's PHEXXI Submitted for Marketing Approval in United Arab Emirates by Pharma 1 Drug Store
- Press releasePRNewswire
Notable Data on Evofem's SOLOSEC in Recurrent Bacterial Vaginosis (BV) Released at ACOG Annual Meeting
- Press releasePRNewswire
Evofem Signs SOLOSEC License Agreement for Middle East with Pharma 1
- Press releaseBusiness Wire
Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics
- Press releasePRNewswire
Evofem Reports First Quarter 2025 Financial Results and Provides Business Update
- Press releaseBusiness Wire
Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™
- Press releaseBusiness Wire
Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune™
- Press releaseBusiness Wire
Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025
- Press releaseGlobe Newswire
Windtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business Updates
- Press releasePRNewswire
Evofem Biosciences to Present at Emerging Growth Conference
- Press releaseBusiness Wire
Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials
- Press releaseBusiness Wire
Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements
- Press releaseBusiness Wire
Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025
- Press releaseBusiness Wire
Upcoming Aditxt Weekly Update to Highlight Pearsanta's Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection
- Press releasePRNewswire
Evofem Reports Fourth Consecutive Year of Net Sales Growth
- Press releaseBusiness Wire
Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk
- Press releasePRNewswire
Evofem Biosciences Announces Financial Results for the Third Quarter of 2024
- Press releasePRNewswire
Evofem Biosciences Announces Financial Results for the Second Quarter of 2024
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.